MDM2 and liposarcoma: Given the almost universal amplification of MDM2 in WDLPS and DDLPS, detection of this genomic aberration in ctDNA could be clinically useful for non-invasive distinction between these liposarcomas and other retroperitoneal tumors in the appropriate clinical context.